CD36抗原缺失与临床输血安全相关研究进展*

doi:10.3969/j.issn.1671-2587.2026.02.021

临床输血与检验 ›› 2026, Vol. 28 ›› Issue (2): 279-285.DOI: 10.3969/j.issn.1671-2587.2026.02.021

CD36抗原缺失与临床输血安全相关研究进展^*

王欣, 李峣, 单卓越, 赵丽艳

吉林大学第二医院,吉林长春 130041

收稿日期:2025-09-17 接受日期:2025-10-28 出版日期:2026-04-20 发布日期:2026-04-22
通讯作者: 赵丽艳,主要从事肿瘤细胞遗传学、肿瘤细胞侵袭转移分子机制、肿瘤合并血栓分子标志物分析、疑难血型与分子诊断等方面研究,（E-mail）zhaoliy@jlu.edu.cn。
作者简介:王欣,主要从事临床检验诊断学方面研究,（E-mail）15577172083@163.com。
基金资助:
^*本课题受吉林省科技发展计划项目（No.20240401068YY）资助

Research Progress on the Relationship between CD36 Antigen Deficiency and Clinical Blood Transfusion Safety

WANG Xin, LI Yao, SHAN Zhuoyue, ZHAO Liyan

The Second Hospital of Jilin University, Changchun 130041

Received:2025-09-17 Accepted:2025-10-28 Online:2026-04-20 Published:2026-04-22

摘要/Abstract

摘要： CD36抗原广泛存在于血小板、单核等细胞表面,但人群中有些个体却表现为CD36抗原缺失。这些个体在接受输血、妊娠等免疫刺激后可产生抗CD36抗体。携带该抗体的患者如再次输注CD36抗原阳性血液制品即有可能发生血小板输注无效、胎儿和新生儿同种免疫性血小板减少症（fetal and neonatal alloimmune thrombocytopenia, FNAIT）、输血后紫癜等输血相关并发症,威胁临床输血安全。本文将对CD36抗原缺失的分子基础以及CD36抗原缺失与血小板输注无效、胎儿和新生儿同种免疫性血小板减少症、输血相关性急性肺损伤的相关性进行综述。

关键词: CD36抗原缺失, 血小板输注无效, 胎儿和新生儿同种免疫性血小板减少症, 输血相关性急性肺损伤, 输血后紫癜

Abstract: The CD36 antigen is widely present on the surface of platelets, monocytes and other cells. However, some individuals in the population show a deficiency of the CD36 antigen. These individuals may produce anti-CD36 antibodies after exposure to immune stimuli such as blood transfusion and pregnancy. Patients carrying this antibody may experience complications related to blood transfusion, such as platelet transfusion refractoriness, alloimmune thrombocytopenia in the fetus and neonate, and post-transfusion purpura, if they receive blood products positive for the CD36 antigen again. This poses a threat to the safety of clinical blood transfusion. This article will review the molecular basis of CD36 antigen deficiency and its correlation with platelet transfusion refractoriness, alloimmune thrombocytopenia in the fetus and neonate, and transfusion-related acute lung injury.

Key words: CD36 antigen deficiency, Platelet transfusion refractoriness, Fetal and neonatal alloimmune thrombocytopenia, Transfusion-related acute lung injury, Post-transfusion purpura

中图分类号:

R457.1

王欣, 李峣, 单卓越, 赵丽艳. CD36抗原缺失与临床输血安全相关研究进展^*[J]. 临床输血与检验, 2026, 28(2): 279-285.

WANG Xin, LI Yao, SHAN Zhuoyue, ZHAO Liyan. Research Progress on the Relationship between CD36 Antigen Deficiency and Clinical Blood Transfusion Safety[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(2): 279-285.

参考文献

[1] Wang J C,Li Y S.CD36 tango in cancer: signaling pathways and functions[J]. Theranostics,2019,9(17): 4893-4908.
[2] Shu H Y,Peng Y Z,Hang W J,et al.The role of CD36 in cardiovascular disease[J]. Cardiovasc Res,2022, 118(1):115-129.
[3] Zhang X D,Fan J H,Li H P,et al.CD36 signaling in diabetic cardiomyopathy[J]. Aging Dis,2021,12(3):826-840.
[4] Yang X C,Okamura D M,Lu X F,et al.CD36 in chronic kidney disease: novel insights and therapeutic opportunities[J]. Nat Rev Nephrol,2017,13(12):769-781.
[5] Yang Y X,Liu X K,Yang D,et al.Interplay of CD36, autophagy,and lipid metabolism: insights into cancer progression[J]. Metabolism,2024,155:155905.
[6] Li Y X,Huang X G,Yang G,et al.CD36 favours fat sensing and transport to govern lipid metabolism[J]. Prog Lipid Res,2022,88:101193.
[7] Smith J,Su X,El-Maghrabi R,et al.Opposite regulation of CD36 ubiquitination by fatty acids and insulin: effects on fatty acid uptake[J]. J Biol Chem,2008,283(20): 13578-13585.
[8] Jiang M Z,Wu N,Xu B,et al.Fatty acid-induced CD36 expression via O-GlcNAcylation drives gastric cancer metastasis[J]. Theranostics,2019,9(18):5359-5373.
[9] Osz K,Russ M,Petrik J.The thrombospondin-1 receptor CD36 is an important mediator of ovarian angiogenesis and folliculogenesis[J]. Reprod Biol Endocrinol,2014, 12:21.
[10] 廖信志. CD36促进肾透明细胞癌血管生成的研究[D].赣南医学院,2023.
[11] 周映君,韦喜敢,周吉成,等. CD36抗原缺失与血小板输注无效关系的研究进展[J]. 临床血液学杂志,2016,29(10): 851-854.
[12] Kashiwagi H,Tomiyama Y,Nozaki S,et al.Analyses of genetic abnormalities in type I CD36 deficiency in Japan: identification and cell biological characterization of two novel mutations that cause CD36 deficiency in man[J]. Hum Genet,2001,108(6): 459-466.
[13] Lee K,Godeau B,Fromont P,et al.CD36 deficiency is frequent and can cause platelet immunization in Africans[J]. Transfusion,1999,39(8):873-879.
[14] Flesch B K,Scherer V,Opitz A,et al.Platelet CD36 deficiency is present in 2.6% of Arabian individuals and can cause NAIT and platelet refractoriness[J]. Transfusion, 2021,61(6):1932-1942.
[15] Yanai H,Chiba H,Fujiwara H,et al.Phenotype-genotype correlation in CD36 deficiency types Ⅰ and Ⅱ[J]. Thromb Haemost,2000,84(3):436-441.
[16] Phuangtham R,Santoso S,Leelayuwat C,et al.Frequency of CD36 deficiency in Thais analyzed by quantification of CD36 on cell surfaces and in plasma[J]. Transfusion, 2020,60(4):847-854.
[17] Liu J,Shao Y,Ding H Q,et al.Distribution of CD36 deficiency in different Chinese ethnic groups[J]. Hum Immunol,2020,81(7):366-371.
[18] 蔡碧红,王嘉励,叶欣,等. 广州地区无偿献血者CD36缺失频率及血小板输注治疗[J]. 实用医学杂志,2020, 36(12):1634-1637.
[19] Lyu Q L,Peng M Z,Chen Q,et al.Frequency and molecular basis of CD36 deficiency among platelet donors in Kunming,China[J]. Platelets,2023,34(1): 2176168.
[20] Wang W,Yan Z,Hu J,et al.Scavenger receptor class B,type 1 facilitates cellular fatty acid uptake[J]. Biochim Biophys Acta Mol Cell Biol Lipids,2020,1865(2):158554.
[21] 王超,吕蓉,胡晓玉,等.CD36抗原缺失Ⅰ型4种碱基突变及蛋白结构生物信息学分析[J].临床输血与检验,2024, 26(6):726-735.
[22] Xu X G,Liu Y,Hong X Z,et al.Variants of CD36 gene and their association with CD36 protein expression in platelets[J]. Blood Transfus,2014,12(4):557-564.
[23] Kashiwagi H,Tomiyama Y,Kosugi S,et al.Family studies of type Ⅱ CD36 deficient subjects: linkage of a CD36 allele to a platelet-specific mRNA expression defect(s) causing type Ⅱ CD36 deficiency[J]. Thromb Haemost, 1995,74(2):758-763.
[24] Lyu Q L,Lin Y W,Pan Y M,et al.The polymorphism analysis for CD36 among platelet donors[J]. Sci Rep, 2024,14(1):8534.
[25] 林凤秋,李晓丰,李剑平. 血小板CD36抗原Ⅱ型缺失与内含子序列多态性的相关性[J]. 中国输血杂志,2022,35(8): 791-795.
[26] Tasaki T,Fujii K,Gotoh K,et al.Pre-transfusion screening for platelet-reactive antibodies[J]. Transfus Apher Sci,2005,33(2):157-164.
[27] Xu X Z,Chen D W,Ye X,et al.Improvement of anti-CD36 antibody detection via monoclonal antibody immobilization of platelet antigens assay by using selected monoclonal antibodies[J]. Ann Lab Med,2023, 43(1):86-91.
[28] Chen X Y,Zhao Y H,Lv Y,et al.Immunological platelet transfusion refractoriness: current insights from mechanisms to therapeutics[J]. Platelets,2024,35(1): 2306983.
[29] Ikeda H,Mitani T,Ohnuma M,et al.A new platelet-specific antigen,Naka,involved in the refractoriness of HLA-matched platelet transfusion[J]. Vox Sang,1989, 57(3):213-217.
[30] 周助人,李剑平. CD36基因缺失与同种免疫性血小板减少症关系的研究进展[J]. 吉林大学学报(医学版),2012, 38(6):1232-1235.
[31] Pedini P,Hicheri Y,Bertand G,et al.A case of platelet transfusion refractoriness in a CD36-negative patient with acute myeloid leukemia: Diagnostic and therapeutic management[J]. Transfusion,2022,62(10): 2148-2150.
[32] Sekayan T,Allen E S,Kopko P,et al.Management challenge of a rare concomitant platelet glycoprotein IV/CD36 and IIb/IIIa deficiencies: Case illustration[J]. Transfusion,2025,65(4):767-772.
[33] Morishita K,Wakamoto S,Miyazaki T,et al.Life-threatening adverse reaction followed by thrombocytopenia after passive transfusion of fresh frozen plasma containing anti-CD36 (Nak) isoantibody[J]. Transfusion,2005,45(5): 803-806.
[34] Wakamoto S,Fujihara M,Urushibara N,et al.Heterogeneity of platelet responsiveness to anti-CD36 in plasma associated with adverse transfusion reactions[J]. Vox Sang,2005,88(1):41-51.
[35] 周燕,钟周琳,卢芳,等. 产妇抗CD36抗体发生率及诱导血小板凋亡的实验研究[J]. 临床血液学杂志,2021,34(8): 531-535.
[36] Cohn C S.Platelet transfusion refractoriness: how do I diagnose and manage?[J]. Hematology Am Soc Hematol Educ Program,2020,2020(1):527-532.
[37] 中国输血协会人类组织抗原专业委员会,中国输血协会免疫血液学专业委员会. 免疫性血小板输注无效的判定及临床实践专家共识[J]. 临床输血与检验,2022,24(3): 273-278.
[38] 何子毅,胡应明,贝孟辉,等. 东莞地区CD36抗原缺失型血小板献血者资料库的建立与分析[J]. 临床输血与检验, 2025,27(4):492-498.
[39] 毛伟,蒋玉林,朱传福,等. 国内血小板基因库建设及应用的现状研究[J]. 临床输血与检验,2024,26(5):656-661.
[40] 徐筠娉,熊镗睿,杨帆,等. CD36抗原表达大规模筛查及阴性供者结构与供能分析[J]. 中国输血杂志,2025,38(5): 615-620.
[41] 朱发明,毛伟,张志欣. 血小板配合性输注的分析和展望[J]. 中国输血杂志,2022,35(11):1097-1100.
[42] Al-Samkari H,Kuter D J.Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment[J]. Semin Thromb Hemost,2020,46(3):275-288.
[43] 赵沛喆,徐熠,梁雅珺,等. 免疫性血小板输注无效预防策略研究进展[J]. 中国输血杂志,2025,38(3):448-454.
[44] Xu X Z,Li L,Xia W J,et al.Successful management of a hydropic fetus with severe Anemia and thrombocytopenia caused by anti-CD36 antibody[J]. Int J Hematol,2018,107(2):251-256.
[45] Xu X Z,Chen D W,Ye X,et al.Successful prenatal therapy for anti-CD36-mediated severe FNAIT by deglycosylated antibodies in a novel murine model[J]. Blood,2021,138(18):1757-1767.
[46] 唐颖怡,陈大伟,夏文杰,等. CD36抗体引起的胎儿新生儿同种免疫性血小板减少症中人脐静脉内皮细胞通透性作用机理的初步研究[J]. 中国输血杂志,2023,36(9):766-770.
[47] 谢文举,付子可,王秋实. 胎儿/新生儿同种免疫性血小板减少症研究进展[J]. 临床输血与检验,2025,27(6):882-888.
[48] 魏亚明,桂嵘,王秋实,等. 血小板抗体检测专家共识[J]. 临床输血与检验,2020,22(1):1-5.
[49] Semple J W,Rebetz J,Kapur R.Transfusion-associated circulatory overload and transfusion-related acute lung injury[J]. Blood,2019,133(17):1840-1853.
[50] Nakajima F,Nishimura M,Hashimoto S,et al.Role of anti-Nak(a) antibody,monocytes and platelets in the development of transfusion-related acute lung injury[J]. Vox Sang,2008,95(4):318-323.
[51] Chen D W,Kang T,Xu X Z,et al.Mechanism and intervention of murine transfusion-related acute lung injury caused by anti-CD36 antibodies[J]. JCI Insight, 2023,8(6):e165142.
[52] 吴泳彬. 抗CD36抗体诱导的小鼠TRALI模型建立及初步机制探讨[D]. 广州:南方医科大学,2020.
[53] 刘晓敏,江颖,刘俊婷,等. 中国人群输血相关急性肺损伤58例文献回顾性分析[J]. 中国输血杂志,2020,33(8): 780-783.
[54] 胡嫒,陈唯韫,黄宇光. 输血相关急性肺损伤发病机制及防治措施研究进展[J]. 中国医学科学院学报,2020,42(5): 674-680.
[55] 范玥,张明燃,梁思敏. 输血相关急性肺损伤2例[J]. 现代临床医学,2024,50(5):340-341.
[56] Padhi P,Parihar G S,Stepp J,et al.Post-transfusion Purpura: a rare and life-threatening aetiology of thrombocytopenia[J]. BMJ Case Rep,2013,2013: bcr2013008860.
[57] Wu G G.Detection of clinically relevant platelet antibodies in the Asian population[J]. ISBT Sci Ser, 2014,9(1):112-117.
[58] Li L L,Zhong Z L,Zhou Y,et al.Platelet donor database: a study on the specialist donor database for the patients with alloimmune thrombocytopenia in the Chinese population and the assessment of completeness[J]. Chin Med J,2021,135(2):234-236.
[59] Bierling P,Godeau B,Fromont P,et al.Posttransfusion Purpura-like syndrome associated with CD36 (Naka) isoimmunization[J]. Transfusion,1995, 35(9):777-782.
[60] Hawkins J,Aster R H,Curtis B R.Post-transfusion Purpura: current perspectives[J]. J Blood Med,2019,10: 405-415.
[61] 徐秀章,陈大伟,夏文杰,等. CD36单克隆抗体体内清除血小板的机制探讨[J]. 临床输血与检验,2025,27(1):48-53.
[62] 贺雪花,乔佳佳,郭效君,等. CD36抗原缺失与输血相关免疫的研究进展[J]. 中国输血杂志,2021,34(12):1408-1411.

CD36抗原缺失与临床输血安全相关研究进展^*

Research Progress on the Relationship between CD36 Antigen Deficiency and Clinical Blood Transfusion Safety

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	刘雯, 王文星, 范娜, 陈伟, 梁静. Th17/Treg平衡及细胞因子水平与血小板输注无效的相关性研究^*[J]. 临床输血与检验, 2026, 28(1): 65-69.
[2]	范成艳, 温玉洁, 廉雪, 张丹, 王洁, 敬媛媛, 王丽君, 李伟, 贾延军, 李冬妹. 免疫性血小板输注无效患者血清中血小板相关抗体的变化及其临床意义^*[J]. 临床输血与检验, 2024, 26(5): 661-666.
[3]	赵嘉璐, 范鑫秋, 曾一梅, 蔡晓红, 李佳明, 王学锋. TUBB1突变型骨髓增生异常综合症患者临床特征及血小板输注无效相关性分析[J]. 临床输血与检验, 2024, 26(5): 683-689.
[4]	温玉洁, 范成艳, 张丹, 李冬妹, 孙铁成, 贾延军, 刘娜. 血小板自身抗体在血小板输注无效中的临床意义^*[J]. 临床输血与检验, 2024, 26(4): 511-515.
[5]	范成艳, 温玉洁, 张丹, 廉雪, 刘娜, 孙铁成, 王东梅, 贾延军, 李冬妹. 免疫性血小板输注无效患者HLA/HPA抗体特性分析及其对血小板输注效果的影响^*[J]. 临床输血与检验, 2024, 26(3): 353-358.
[6]	乔剑, 刁春红, 于洋, 张娜, 常梦远. 吴茱萸碱通过调节HMGB1/TLR4/NF-κB信号通路减轻大鼠输血相关性急性肺损伤^*[J]. 临床输血与检验, 2023, 25(5): 599-606.
[7]	刘铮, 孙亚敏, 邵树军, 康轶青, 王子清, 李建斌. 血小板输注无效患者的HLA-I类抗体特性分析^*[J]. 临床输血与检验, 2023, 25(5): 631-635.
[8]	中国输血协会人类组织抗原专业委员会, 中国输血协会免疫血液学专业委员会. 免疫性血小板输注无效的判定及临床实践专家共识^*[J]. 临床输血与检验, 2022, 24(3): 273-278.
[9]	敬媛媛, 王洁, 李冬妹, 王丽君, 范成艳, 贾延军. 免疫性血小板输注无效患者HLA和/或HPA抗体产生的影响因素分析[J]. 临床输血与检验, 2021, 23(6): 723-727.
[10]	唐雯, 袁君, 严京梅, 吴毅, 齐清, 栾建凤, 刘太香, 吴敏慧, 史丽莉, 冯晨晨, 薛敏. 抗体特异性预测方法克服HLA-Ⅰ类抗体所致血小板输注无效患者1例^*[J]. 临床输血与检验, 2021, 23(6): 797-799.
[11]	王皓, 郭兴莹, 张志波, 张新萍, 冀春红, 黄象艳. HLA与HPA配型不合导致血小板输注无效1例[J]. 临床输血与检验, 2020, 22(3): 334-336.
[12]	黄雪原, 陈秉宇, 周明, 马现君, 陈静, 许红, 蔡丹, 胡俊, 谢毓滨, 桂嵘, 王勇军. 血小板抗体检测的多中心临床应用调查——基于中国10家单位的2 338例病例对照研究[J]. 临床输血与检验, 2020, 22(2): 113-117.
[13]	李冬妹, 王洁, 敬媛媛, 单小燕, 贾延军. 血小板输注无效患者体内C1q-HLA抗体的临床意义[J]. 临床输血与检验, 2020, 22(2): 126-130.
[14]	王贵强, 林新梅, 冯均建, 张莉, 卫茂华. 血清KL-6在输血相关性急性肺损伤中应用价值研究[J]. 临床输血与检验, 2019, 21(5): 449-453.
[15]	刘正婷, 黄佳丽, 陈尚良. 二孩时代,我们能为FNAIT做些什么[J]. 临床输血与检验, 2019, 21(5): 552-557.